GlassScriptPhysician profile
Ahmed Khattab
NPI 1265736268
$70,112.21
in general payments reported to CMS, 2019-2025
13 companies · $44K in 2025
The $44K reported for 2025 was more than what 97% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.64 · 2022: $101 · 2023: $1,251 · 2024: $25K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $48K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $2,305 · Travel and Lodging: $1,244 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $48,021.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,300.00 |
| Food and Beverage | $2,305.36 |
| Travel and Lodging | $1,244.26 |
| Education | $117.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $65,855.24 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $1,240.15 | 2024 | Strensiq |
| Antares Pharma, INC. | $1,200.00 | 2023 | |
| Eton Pharmaceuticals, INC. | $737.04 | 2023-2025 | Alkindi, Increlex, Khindivi |
| Tolmar, INC. | $290.69 | 2024-2025 | Fensolvi |
| Sanofi-Aventis U.S. LLC | $235.56 | 2024 | |
| Biomarin Pharmaceutical INC. | $234.27 | 2024-2025 | Voxzogo 1.2mg |
| Kyowa Kirin, INC. | $139.42 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $101.30 | 2022 | |
| Boston Scientific Corporation | $37.75 | 2023-2024 | Acquire |
| Medtronic Minimed, INC. | $22.64 | 2019 | |
| Incyte Corporation | $18.15 | 2025 | Jakafi, Niktimvo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Khattab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.